Welcome to our dedicated page for Cocrystal Pharma news (Ticker: COCP), a resource for investors and traders seeking the latest updates and insights on Cocrystal Pharma stock.
Cocrystal Pharma, Inc. (Nasdaq: COCP) is a clinical-stage biotechnology company developing antiviral therapeutics that target the replication machinery of viruses such as influenza viruses, coronaviruses, noroviruses and hepatitis C viruses. This news page compiles company announcements, press releases and regulatory disclosures so readers can follow Cocrystal’s scientific, clinical and corporate developments over time.
Visitors can review updates on CDI-988, Cocrystal’s oral pan-viral 3CL protease inhibitor being advanced as a potential prevention and treatment for norovirus infections and for coronavirus infections. Recent news has highlighted FDA Investigational New Drug (IND) clearance, a Study May Proceed Letter for a Phase 1b human challenge study, Institutional Review Board approval at Emory University School of Medicine, and previously reported favorable Phase 1 safety and tolerability data.
The feed also covers progress in the company’s influenza programs, including oral and inhaled CC-42344 for pandemic and seasonal influenza A and an influenza A/B polymerase complex program supported by a National Institutes of Health Small Business Innovation Research (SBIR) Phase I award. Articles describe human challenge studies, preclinical findings against highly pathogenic avian influenza strains and external validation through government funding.
In addition to R&D news, this page includes capital markets and corporate updates, such as registered direct offerings, private placements of common stock and warrants, and conference presentations where Cocrystal’s leadership provides company overviews and clinical progress updates. Investors and observers can use this centralized news stream to follow key milestones, including clinical trial initiations, data presentations, grant awards and financing transactions related to COCP.
Cocrystal Pharma, Inc. (NASDAQ: COCP) reported its Q1 2020 financial results, highlighting a revenue decline to approximately $461,000 from $5,078,000 in Q1 2019, attributed to a previous one-time income related to the Merck collaboration. The company anticipates sufficient capital to fund operations through 2021, holding approximately $21.7 million in cash as of March 31, 2020. Key advancements include licensing agreements with Kansas State University for broad-spectrum antiviral development and successful completion of a Phase 2a clinical trial for HCV treatment.
Cocrystal Pharma (NASDAQ: COCP) has announced a reprioritization of its clinical development activities due to the impact of the COVID-19 pandemic, focusing on its preclinical COVID-19 program. The company continues its collaboration with Merck on influenza A/B antiviral agents, which may yield up to $156 million in milestone payments. However, supply chain disruptions have delayed the influenza A virus program. The company is progressing in its Norovirus program, with proof-of-concept studies expected to conclude in Q4 2020.